Evaluation of Liver Injury - PowerPoint PPT Presentation

About This Presentation
Title:

Evaluation of Liver Injury

Description:

Title: Liver Function Tests (LFTs) Author: Mark Czaja Last modified by: zana.nikolla Created Date: 3/14/1997 1:19:46 PM Document presentation format – PowerPoint PPT presentation

Number of Views:294
Avg rating:3.0/5.0
Slides: 60
Provided by: MarkC272
Learn more at: https://jacobimed.org
Category:

less

Transcript and Presenter's Notes

Title: Evaluation of Liver Injury


1
Evaluation of Liver Injury
  • Mark J. Czaja
  • Liver Research Center
  • Albert Einstein College of Medicine Bronx, N.Y.

2
Liver Function Tests
  • Alanine aminotransferase (ALT)
  • Aspartate aminotransferase (AST)
  • Lactate dehydrogenase (LDH)
  • Alkaline phosphatase
  • Bilirubin
  • Albumin

3
Mechanisms of Liver Dysfunction
  • Direct cellular injury
  • Blockage in bile flow
  • Impaired blood flow

4
Direct Cellular Injury - HCV Infection
5
Blockage in Bile Flow - Biliary Atresia
6
Impaired Blood Flow - CHF
7
Consequences of Liver Injury
liver cell injury
liver cell death
proliferation
matrix deposition
sufficient
inadequate
altered architecture
recovery
liver failure
cirrhosis
8
Types of Liver Tests
  • True tests of liver function
  • Biochemical markers of liver injury
  • Biochemical markers of specific liver diseases

9
Testable Biochemical Liver Function
  • Ability to transport organic anions
  • Capacity to metabolize certain substances
  • Capability to synthesize various proteins

10
Steps in Organic Anion Transport
  • Delivery and uptake
  • Metabolic alteration
  • Secretion and excretion

11
Bilirubin
  • Tetrapyrole
  • Toxic in neonates - kernicterus
  • Derived from
  • Senescent RBC (70-80)
  • Hemoproteins (20-30)
  • Ineffective erythropoiesis

12
Bilirubin Formation
heme
biliverdin
heme
biliverdin
bilirubin
oxygenase
reductase
Transport hydrophobic due to internal
H-bonding circulates bound to
albumin
13
Bilirubin Metabolism
Bile
Plasma
Hepatocyte
Alb UCB
BMG BDG
UCB ligandin
BMG BDG
glucuronyl
transferase
BMG BDG
14
Bilirubin Elimination
  • Intestine
  • BMG (20) BDG (80) UCB (trace)
  • Deconjugated to urobilinogen
  • Excreted or reab-sorbed (20)
  • Urine
  • BMG and BDG
  • No UCB

15
Measurement of Serum Bilirubin
  • Normal concentration lt 1 mg/dl
  • Conjugated lt 5
  • Jaundice if gt 3 mg/dl
  • Detected by diazo reaction - cleaved to
    colored azo-dipyrole
  • Conjugated reacts rapidly (direct)
  • Unconjugated reacts slowly (indirect)

16
Differential Diagnosis I
  • Prehepatic
  • Intrahepatic
  • Congenital
  • Acquired
  • Posthepatic

17
Differential Diagnosis II
  • Unconjugated hyperbilirubinemia
  • Increased bilirubin production (hematological)
  • Decreased uptake (drug)
  • Decreased conjugation (congenital)
  • Conjugated hyperbilirubinemia
  • Congenital
  • Drug
  • Liver disease
  • Biliary obstruction

18
Inherited Disorders Causing Unconjugated
Hyperbilirubinemia
  • Crigler-Najjar syndrome
  • Type 1 absent GT
  • Type 2 reduced GT activity
  • Gilberts syndrome reduced GT activity due to
    genetic defect in TATAA element of GT promoter

19
Inherited Disorders Causing Conjugated
Hyperbilirubinemia
  • Dubin-Johnson syndrome mutations in multidrug
    resistance associated protein 2 (MRP2)
  • Rotors syndrome genetic defect

20
Hepatic Metabolic Capacity
  • Clearance must depend on total functional mass
    or metabolic activity
  • Hepatic drug metabolism - 14Camino-pyrine
    breath test
  • Galactose elimination
  • Not used clinically

21
Hepatic Synthetic Capacity
  • Most major plasma proteins are made in the liver
  • Decreased hepatocytes decreased protein
    synthesis and release
  • Albumin and coagulation factors are clinically
    important

22
Albumin
  • 50 of all synthesized hepatic protein
  • Determinant of plasma oncotic pressure
  • Important transport protein

23
Serum Albumin Levels
  • Long half-life of 20 days
  • Large hepatic synthetic reserve
  • Decreased with persistent, large injury
  • Decreased in chronic liver disease
  • Poor prognostic sign

24
Non-hepatic Causes of Hypoalbuminemia
  • Severe malnutrition
  • Renal or GI loss
  • Glomerulopathy, HIV enteropathy
  • High catabolism
  • Infections, burns

25
Coagulation Factors
  • Half-lives of hours to days
  • Liver synthesizes I, II, V, VII, IX, and X
  • Large synthetic reserve

26
Prothrombin Time (PT)
  • PT detects abnormalities in I, II, V, VII and X
    (extrinsic pathway)
  • PT is increased in liver disease
  • Best prognostic indicator
  • Acute liver disease
  • Chronic liver disease

27
Non-hepatic Causes of Elevated PT
  • Congenital coagulation factor deficiencies
  • Consumptive coagulopathies
  • Vitamin K deficiency (II, VII, IX, X)

28
To Rule Out Vitamin K Deficiency
  • Any patient with an elevated PT
  • Parental vitamin K for 3 days
  • Normalization of PT - vitamin K deficiency
  • Failure to normalize - hepatocellular disease

29
Serum Immunoglobulins
  • Not produced by hepatocytes
  • Frequently elevated in liver disease
  • Secondary to inflammatory process
  • ? produced by antigen shunting

30
Biochemical Markers of Liver Injury
31
Liver Enzymes
  • Low levels always present in serum
  • Leak out from cell after injury
  • Very sensitive
  • Magnitude of abnormality does not correlate well
    with degree of injury

32
Aspartate Aminotransferase (AST)
  • Serum glutamic-oxaloacetic transaminase (SGOT)
  • Transfers an a-amino group of aspartate to a-keto
    group of ketoglutaric acid
  • Present in skeletal muscle, kidney, brain

33
Alanine Aminotransferase (ALT)
  • Serum glutamic-pyruvic transaminase (SGPT)
  • Transfers an a-amino group of alanine to a-keto
    group of ketoglutaric acid
  • Present principally in liver

34
AST and ALT
  • Elevated in most liver diseases
  • Highest levels are in acute liver diseases
  • Only slight elevations in chronic liver diseases
  • Usually increase in parallel

35
AST/ALT in Alcoholic Hepatitis
  • Transaminases rarely exceed 300
  • ASTALT gt2

36
Factors Affecting AST/ALT
  • Depressed by pyridoxine (vit. B6) deficiency
  • Decreased by uremia and renal dialysis

37
AST/ALT Controversies
  • Should lower normal limits be used in females?
  • Females lt 30 vs. males lt 40
  • Are the normal limits too high?
  • Females lt 20 and males lt 30

38
Lactate Dehydrogenase (LDH)
  • Component of classic LFTs
  • Highly non-specific

39
Tests of Impaired Hepatic ExcretionIncreased In
  • Cholestasis
  • Intra-hepatic biliary tract obstruction
  • Extra-hepatic biliary obstruction

40
Alkaline Phosphatase
  • Hydrolyzes phosphate esters at alkaline pH
  • Also present in bone, kidney, placenta, intestine
  • Mainly liver and bone in adults
  • Increased in children from bone growth
  • Placental form during pregnancy

41
Elevated Alkaline Phosphatase
  • Can occur in any liver disease
  • Highest with cholestasis or biliary tract
    obstruction
  • Elevated in infiltrative diseases
  • Due to increase synthesis and secretion

42
Alkaline Phosphatase Isoenzymes
Source Heat Inactivation 5' NT GGTP
Liver Moderate
Bone Rapid - -
Placenta Slow - -
Intestine Slow - -
43
5'-Nucleotidase
  • Hydrolyzes 5'- adenosine monophosphate
  • Mainly present in liver
  • Increases along with alkaline phosphatase

44
g-Glutamyl Transpeptidase(GGTP)
  • Transfers g-glutamyl groups
  • Widely distributed
  • Sensitive correlate to alkaline phosphatase
  • Non-specific (alcoholism, MI, DM, pancreatic
    disease, renal failure)

45
Biochemical Markersof Specific Liver Diseases
46
Etiology-specific Liver Tests
  • Viral hepatitis serologies
  • Serum ferritin level
  • Ceruloplasmin level
  • Alpha1-antitrypsin level
  • Antimitochondrial antibody titer

47
Viral Hepatitis Serology
  • HAV anti-HAV IgM and IgG
  • HBV HBsAg, anti-HBsAg, and anti-HBcAg
  • HCV anti-HCV, HCV RNA

48
Serum Ferritin
  • Widely distributed storage protein
  • Levels reflect body iron stores
  • Elevated in primary hemochromatosis
  • Elevated in acute inflammation and cirrhosis

49
Serum Ceruloplasmin
  • Copper-binding protein
  • Decreased in 95 of patients with Wilsons
    disease
  • 20 of heterozygotes have decreased levels

50
a1-Antitrypsin
  • Inhibits serum trypsin
  • Major component of a1-globulin
  • Deficiency cause of neonatal hepatitis

51
Antimitochondrial Antibody(AMA)
  • Directed against mitochondrial enzyme pyruvate
    dehydrogenase complex
  • Positive in 90 of patients with primary biliary
    cirrhosis

52
Interpretation of Abnormal LFTs
  • Examine multiple tests
  • Consider non-hepatic causes
  • Determine the most abnormal tests

53
Hepatocellular vs. Cholestatic
Test Hepatocellular Cholestatic
ALT/AST 2-3 NL-1
Alk Phos NL-1 2-3
Bilirubin NL-3 NL-3
Albumin NL-3 NL
PT NL-3 NL
54
Case 1
25 yo IVDA c/o 1 week of nausea, vomiting, and
myalgias. Physical exam revealed jaundice.
  • ALT 2045 (15-45)
  • AST 2300 (15-45)
  • Alk Phos 273 (50-150)
  • Bili 3.9 (0.1-1.0)
  • Alb 4.2 (3.5-5.5)
  • PT 11.5 (10-12)

55
Hepatocellular W/U
H P EtOH, medications, transfusions
Risk for viral hepatitis
Risk factors for NASH
Autoimmune features
Etiology-specific LFTs
USG and liver biopsy
56
HBV Infection - HBcAg Staining
57
Case 2
67 yo c/o several months of weight loss, and 1
week of nausea, vomiting, and myalgias. Physical
exam revealed cachexia and jaundice.
  • ALT 75 (15-45)
  • AST 115 (15-45)
  • Alk Phos 650 (50-150)
  • Bili 10.2 (0.1-1.0)
  • Alb 4.2 (3.5-5.5)
  • PT 11.0 (10-12)

58
Cholestatic W/U
H P medications, gallstones, weight loss
USG
dilated ducts
normal
AMA
ERCP
liver biopsy
59
Pancreatic Carcinoma - ERCP
Write a Comment
User Comments (0)
About PowerShow.com